Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · MONO PHARMACARE LIMITED · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
MONO PHARMACARE LIMITED NSE: MONOPHARMA
MONO PHARMACARE LIMITED
StateQ2 FY26 filed
Last close · 27 Oct 2026₹8.90
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · — · —
MONO PHARMACARE LIMITED is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY25–FY25 (all audited; no estimate years)
₹ crore · consolidated
FY25
Revenue
168
EBITDA (ex other income)
—
margin %
—
Owners' profit
—
EPS, as reported (₹)
1.75
ROE % · ROCE %
— · 14.8
Debt / equity (x)
—
Cash from operations
(4)
Capex
(0)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MONO PHARMACARE LIMITED · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 2 quarters
₹ crore
Q4 FY25
Q2 FY26
Revenue
81
66
Profit before tax
1
0
Net profit
—
—
EPS (₹)
0.45
0.00
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MONO PHARMACARE LIMITED · 28 October 2026Page 3 of 3
Exhibit 3: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
27 Oct 2026 · Corporate governance report not required for September 2026 quarter
compliance
minimal
—
—
27 Oct 2026 · Corporate governance filing not required for Q2 FY2026-27
compliance
minimal
—
—
27 Oct 2026 · No share conversion requests in quarter ended September 30, 2026
compliance
minimal
—
—
15 Oct 2026 · No corporate governance report needed for Q1 FY27, says Mono Pharmacare
compliance
minimal
—
—
15 Oct 2026 · Corporate Governance Report Not Applicable for Q1 FY26-27
compliance
minimal
—
—
15 Oct 2026 · Demat compliance certificate filed for quarter ended June 2026
compliance
minimal
—
—
2 Oct 2026 · Mono Pharmacare AGM 2026: All 4 resolutions passed with 100 percent approval
board shareholder meetings
low
—
—
30 Sept 2026 · Mono Pharmacare AGM held Sept 30, 2026; financials adopted, auditor and director reappointed
board shareholder meetings
low
—
—
28 Sept 2026 · Trading Window Closure from Oct 1 for H2 FY26 Results
compliance
minimal
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
